| abstract |
The present disclosure relates generally to novel compounds of formula (I) and pharmaceutically acceptable salts that are CGRP-receptor antagonists. The present disclosure also provides for the treatment of CGRP related disorders, including migraines and other headaches, neurovascular expansion, neurological inflammation, heat damage, circulating shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). To pharmaceutical compositions and methods for use of such compounds in (I) |